ANALYSTS HAVE TRADITIONALLY DISLIKED BRAND-GENERIC COMBINATION COMPANIES, but there are many reasons to challenge this prevailing false assumption. Bolting on a revenue stream that is not as difficult to achieve as a new brand drug gives a company operating and R&D revenues. Impax Labs has successfully funded its R&D efforts from sales of generics, and without that capital source would have needed to finance R&D externally. Rethink sustainable business models.
http://lnkd.in/D-5Ye6
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022